Related Experiment Video
Updated: Jul 26, 2025
11:15
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
24.4K
CK-7 negative primary lung adenocarcinoma
Dimitri Tchienga1, Noelani-Mei Ascio1, Abid Qureshi2
1Department of Surgery, St George's University School of Medicine, True Blue, Grenada, WI, USA.
Journal of Surgical Case Reports
|June 19, 2023
Summary
Cytokeratin 7 negativity can complicate lung adenocarcinoma diagnosis. Utilizing additional immunomarkers like thyroid transcription factor 1 and Napsin A is crucial for accurate pulmonary diagnosis.
Area of Science:
- Pathology
- Oncology
- Cytology
Background:
- Cytokeratin 7 (CK7) is a common marker for lung adenocarcinoma (ADC).
- Accurate diagnosis of pulmonary ADC is critical for appropriate patient treatment.
- Diagnostic challenges can arise from atypical marker expression.
Observation:
- This paper reports rare cases of pulmonary adenocarcinoma exhibiting negativity for Cytokeratin 7.
- CK7 negativity presents a diagnostic hurdle in identifying lung adenocarcinoma.
- Standard diagnostic protocols may be insufficient in these specific cases.
Findings:
- Pulmonary adenocarcinomas can be negative for Cytokeratin 7.
- A combination of immunomarkers is necessary for definitive diagnosis when CK7 is absent.
- Recommended markers include thyroid transcription factor 1, Napsin A, p40, p63, and CK20.
Implications:
- Diagnostic algorithms for lung adenocarcinoma must account for CK7-negative variants.
- The use of a panel of immunomarkers enhances diagnostic accuracy for challenging cases.
- This finding aids pathologists in correctly diagnosing pulmonary ADC, improving patient outcomes.
